ACE inhibitors are linked to increased lung cancer risk, study finds

  title={ACE inhibitors are linked to increased lung cancer risk, study finds},
  author={Zosia Kmietowicz},
  journal={British Medical Journal},
  • Z. Kmietowicz
  • Published 24 October 2018
  • Medicine
  • British Medical Journal
Angiotensin converting enzyme inhibitors (ACEIs) are associated with a higher risk of lung cancer than angiotensin receptor blockers (ARBs), especially if used for more than five years, a study in The BMJ has found.1 Although the risk to individual patients is modest, the absolute numbers of patients at risk for lung cancer is potentially large because ACEIs are widely prescribed, said the researchers. Evidence suggests that ACEIs increase the risk of lung cancer through the build-up of… Expand
The effects of two types of renin-angiotensin system inhibitors on the hypertension induced by new pressor protein associated with beta-factor XIIa in rats
It could be concluded that losartan could improve hypertension in normal rats, while captopril deteriorated hypertension in bilaterally nephrectomized rats in this hypertension model. Expand
A modular map of Bradykinin-mediated inflammatory signaling network
The development of a pathway resource of signaling events mediated by bradykinin will facilitate the identification of novel candidates as therapeutic targets for diseases associated with dysregulated bradykinsin signaling. Expand


Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study
In this population based cohort study, the use of ACEIs was associated with an increased risk of lung cancer, and the association was particularly elevated among people using ACEIs for more than five years. Expand
Angiotensin converting enzyme inhibitors and lung cancer
Any extra risk must be balanced against the mortality benefits of ACEI use to decide whether to continue using ACEI in patients with a history of heart attack or stroke. Expand